Pulmonary Deposition of Ultrasound Rock Salt Aerosol Inhalation Therapy

Condition(s) studied

Investigational drug(s) / intervention(s)

USN before SVN: The group that received ultrasonic rock salt aerosol inhalation therapy followed by small-volume nebulized inhalation therapy.

SVN before USN: The group that received small-volume nebulized inhalation therapy followed by ultrasonic rock salt aerosol inhalation therapy.

Study summary

In the in vitro modeling phase, the investigators plan to use a realistic human upper respiratory tract model and an asymmetric ideal bronchial tree model. By combining 3D printing experiments with CFD simulations, the investigators will investigate the respiratory tract deposition rate and distribution of micro - moist particles in ultrasound rock salt aerosol inhalation therapy. This will be compared with a small - volume nebulizer to verify the effectiveness of ultrasound rock salt aerosol inhalation therapy and lay the foundation for further research on the application of this inhalation technique to other drug formulations.

In the clinical phase, the investigators plan to have subjects inhale radioactive aerosols and use PET/CT imaging technology to assess the deposition rate of aerosol particles in the lungs. By quantitatively analyzing the images, the investigators will study their distribution characteristics in real human bodies to verify the accuracy of the in vitro models and the potential for clinical application.

Eligibility

Primary outcome measure(s)

• In Vitro Model Pulmonary Deposition Rate — Immediately after nebulization
  Aerosol lung deposition rate calculated by in vitro model
• Pulmonary Drug Deposition Rate — Immediately after nebulization
  Defined as the percentage of drug deposition in the lungs, relative to the whole inhalation volume

Trial sites (1)

Other trials for the same condition